Shire completes $5.9B buyout of Dyax; FDA approves Botox for treating lower limb spasticity;

@FiercePharma: Veterinarian turns dog owner's tragedy into cloud-based EHR for pets. More | Follow @FiercePharma

@EricPFierce: #EMA suspends Hubei Hongyuan Pharmaceutical after Czech inspectors find dust-covered plant and equipment. Story | Follow @EricPFierce

@CarlyHFierce: Glaxo CEO: Consumer health can stand on its own, but don't expect a quick spinoff. Article | Follow @CarlyHFierce

> Shire ($SHPG) today said it had completed its $5.9 billion buyout of Massachusetts-based Dyax, a buy that it says could bring $2 billion in sales. Release

> Allergan ($AGN) says the FDA has approved Botox for the treatment of lower limb spasticity in adult patients to decrease the severity of increased muscle stiffness in ankle and toe muscles. Release

> Sun Pharmaceutical has gotten approval from the Competition Commission of India to sell two marketing divisions to Strides Shasun. Story

Medical Device News

@FierceMedDev: Video game neuro therapy company Akili Interactive raises $30M+. More | Follow @FierceMedDev

@EmilyWFierce: Shkreli's 5th Amendment hall pass rejected for congressional drug pricing hearing. Story | Follow @EmilyWFierce

> Mayo Clinic dispatches UV-emitting robots to fight drug-resistant bacteria. More

> St. Jude recalling some defibrillator leads due to poor insulation. Story

Biotech News

@FierceBiotech: Sanofi's reportedly on the verge of 'sizable' job cuts as diabetes business sputters. Story | Follow @FierceBiotech

@JohnCFierce: You've got to have a code for Twitter: Rule #1. If you want to poke at me, fine. But if you're anonymous, you get blocked. #comeoutandplay. | Follow @JohnCFierce

@DamianFierce: The $SRPT cancellation robbed us of a situation in which Ed Kaye and Janet Woodcock are trapped in White Oak and have to unite to survive. | Follow @DamianFierce

> Sanofi's reportedly on the verge of 'sizable' job cuts as diabetes business sputters. Story

> Astellas is still struggling to close its $379M Ocata buyout. Article

Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.